Choi Pil Cho, Kim Hong Joo, Choi Woo Hyuk, Park Dong Il, Park Jung Ho, Cho Yong Kyun, Sohn Chong Il, Jeon Woo Kyu, Kim Byung Ik
Department of Emergency Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University, Seoul, Korea.
Liver Int. 2009 Feb;29(2):221-6. doi: 10.1111/j.1478-3231.2008.01803.x. Epub 2008 Jun 9.
BACKGROUND/AIMS: There has been no report concerning the predictive capability of each scoring system in determining the development of complications of liver cirrhosis such as variceal bleeding and/or hepatic encephalopathy.
We retrospectively studied 128 patients with liver cirrhosis [92 males; mean (standard deviation) 54.2 (11.2) years] admitted to our institution from March 2004 to April 2006. Seventy-three patients (57.0%, group 1) were admitted because of complications of cirrhosis and 55 patients (43.0%, group 2) were admitted for causes unrelated to complications of cirrhosis. We calculated values for model for end-stage liver disease (MELD), MELD-sodium (MELD-Na) and Child-Turcotte-Pugh (CTP) scores on admission and at 3 and 6 months before admission. Each delta score was defined as the difference in the scores of 3 and 6 months before admission.
The relative risk for complications in the patients with DeltaMELD/3 months >/=1.35, DeltaMELD-Na/3 months >/=1.35 and DeltaCTP/3 months >/=1 was 2.05 [95% confidence intervals (CI) 1.47-2.85, P<0.01], 2.04 (95% CI 1.45-2.88, P<0.01) and 1.98 (95% CI 1.39-2.81, P<0.01) respectively. The area under the receiver-operating characteristic curves of DeltaMELD/3 months, DeltaMELD-Na/3 months and DeltaCTP/3 months for the occurrence of cirrhotic complications were 0.691, 0.694 and 0.722 respectively. A higher DeltaMELD/3 months (>/=1.35), DeltaMELD-Na/3 months (>/=1.35) and DeltaCTP/3 months (>/=1) was associated with decreased survival.
Delta model for end-stage liver disease/3 months, DeltaMELD-Na/3 months and DeltaCTP/3 months were clinically useful parameters for predicting the occurrence of cirrhotic complications.
背景/目的:关于每种评分系统在确定肝硬化并发症(如静脉曲张出血和/或肝性脑病)发生方面的预测能力,尚无相关报道。
我们回顾性研究了2004年3月至2006年4月期间入住我院的128例肝硬化患者[92例男性;平均(标准差)年龄54.2(11.2)岁]。73例患者(57.0%,第1组)因肝硬化并发症入院,55例患者(43.0%,第2组)因与肝硬化并发症无关的原因入院。我们计算了入院时以及入院前3个月和6个月时的终末期肝病模型(MELD)、MELD-钠(MELD-Na)和Child-Turcotte-Pugh(CTP)评分值。每个差值评分定义为入院前3个月和6个月评分的差值。
DeltaMELD/3个月≥1.35、DeltaMELD-Na/3个月≥1.35和DeltaCTP/3个月≥1的患者发生并发症的相对风险分别为2.05[95%置信区间(CI)1.47-2.85,P<0.01]、2.04(95%CI 1.45-2.88,P<0.01)和1.98(95%CI 1.39-2.81,P<0.01)。DeltaMELD/3个月、DeltaMELD-Na/3个月和DeltaCTP/3个月预测肝硬化并发症发生的受试者工作特征曲线下面积分别为0.691、0.694和0.722。较高的DeltaMELD/3个月(≥1.35)、DeltaMELD-Na/3个月(≥1.35)和DeltaCTP/3个月(≥1)与生存率降低相关。
终末期肝病模型/3个月差值、DeltaMELD-Na/3个月差值和DeltaCTP/3个月差值是预测肝硬化并发症发生的临床有用参数。